Bladderchek: diagnostic test for bladder cancer

Purins A, Hiller JE
Record ID 32012000243
Authors' recomendations: The BladderChek assay offers rapid point of care diagnosis of patients being assessed for bladder cancer; giving a moderately sensitive result. It lacks in specificity when compared to the standard, non-invasive test urinary cytology. To overcome the lack of specificity the clinician must exclude several other possible causes of symptoms otherwise BladderChek will have a high false positive rate. The fact that other tests and examinations must be concluded before BladderChek is accurate undermines its utility as a point of care test. Other tests have better sensitivity and specificity and are available commercially, and many more markers are currently being assessed for future clinical use. Therefore as point-of-care tests for bladder cancer are rapidly evolving and show much promise HealthPACT have recommended that this technology be monitored for more information in 24 months time.
Project Status: Completed
Year Published: 2007
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Australia
MeSH Terms
  • Urinalysis
  • Point-of-Care Systems
Organisation Name: Adelaide Health Technology Assessment
Contact Address: School of Public Health, Mail Drop 545, University of Adelaide, Adelaide SA 5005, AUSTRALIA, Tel: +61 8 8313 4617
Contact Name:
Contact Email:
Copyright: Adelaide Health Technology Assessment (AHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.